Skip to main content
. 2023 Jan 30;19(1):2169531. doi: 10.1080/21645515.2023.2169531

Figure 10.

Figure 10.

Ranking diagram of PD-L1 TPS 1–49% and TPS ≥50% subgroups. (a) Ranking diagram of OS of NSCLC patients with PD-L1 1–49%; (b) Ranking diagram of PFS of NSCLC patients with PD-L1 1–49%; (c) Ranking diagram of OS of NSCLC patients with PD-L1 ≥ 50%; (d) Ranking diagram of PFS of NSCLC patients with PD-L1 ≥ 50%. Atez: atezolizumab; Chem: chemotherapy; Nivo: nivolumab; Ipil: ipilimumab.